^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Enhertu (fam-trastuzumab deruxtecan-nxki)

    i
    Company:
    AstraZeneca, Daiichi Sankyo
    Drug class:
    Topoisomerase I inhibitor, HER2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer (KEYNOTE-797) (NCT04042701)
    Phase 1
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/10/2020
    Primary completion :
    07/01/2025
    Completion :
    08/01/2025
    EGFR • HER-2 • BRAF • ALK • ROS1
    |
    HER-2 positive • BRAF V600E • EGFR mutation • HR positive • BRAF V600 • HER-2 expression • HER-2 underexpression • ALK mutation • ROS1 fusion
    |
    Keytruda (pembrolizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies (CERTIS1) (NCT05417594)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    06/24/2022
    Primary completion :
    08/28/2026
    Completion :
    08/28/2026
    HER-2 • BRCA1 • BRCA2 • IDH1 • IDH2 • HRD • BRCA • RAD51C • RAD51D
    |
    HER-2 negative • PALB2 mutation • RAD51C mutation • RAD51D mutation
    |
    temozolomide • Enhertu (fam-trastuzumab deruxtecan-nxki) • Datroway (datopotamab deruxtecan) • AZD9574
    A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) (NCT04539938)
    Phase 2
    Seagen, a wholly owned subsidiary of Pfizer
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    12/01/2020
    Primary completion :
    07/15/2024
    Completion :
    07/01/2025
    HER-2
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)
    Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial (NCT04704661)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    08/09/2021
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    HER-2 • TP53 • ATM • RAS • CD4
    |
    HER-2 positive • TP53 mutation • HER-2 amplification • HER-2 expression • RAS mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • ceralasertib (AZD6738)
    An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis (NCT05376878)
    Phase 4
    City of Hope Medical Center
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    12/21/2022
    Primary completion :
    02/25/2026
    Completion :
    02/25/2026
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trazimera (trastuzumab-qyyp)
    Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN) (NCT05845450)
    Phase 2
    Gruppo Oncologico del Nord-Ovest
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    05/11/2023
    Primary completion :
    05/01/2026
    Completion :
    05/01/2028
    HER-2 • KRAS • BRAF • TMB • MSI • POLE • POLD1
    |
    HER-2 positive • MSI-H/dMMR • KRAS G12C • HER-2 amplification • HER-2 mutation • POLE mutation • KRAS wild-type • RAS wild-type • KRAS G12 • POLD1 mutation • HER-2 positive + HER-2 overexpression • HER-2 positive + RAS wild-type
    |
    Imfinzi (durvalumab) • Vectibix (panitumumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Lumakras (sotorasib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DESTINY-Breast07) (NCT04538742)
    Phase 1/2
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    12/28/2020
    Primary completion :
    01/31/2025
    Completion :
    01/31/2030
    HER-2 • PGR
    |
    HER-2 positive • HR positive
    |
    Imfinzi (durvalumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)
    Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DO-01) (NCT06819007)
    Phase 3
    Daiichi Sankyo
    Not yet recruiting
    Last update posted :
    02/11/2025
    Initiation :
    03/01/2025
    Primary completion :
    11/01/2028
    Completion :
    01/31/2032
    HER-2
    |
    Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer (ADAPTHER2-IV) (NCT05704829)
    Phase 2
    West German Study Group
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    02/05/2024
    Primary completion :
    06/01/2026
    Completion :
    06/01/2028
    HER-2
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer (DESTINY-BTC01) (NCT06467357)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    08/12/2024
    Primary completion :
    06/12/2028
    Completion :
    05/16/2029
    HER-2
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • rilvegostomig (AZD2936)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (Morpheus-TNBC) (NCT03424005)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/30/2018
    Primary completion :
    05/03/2028
    Completion :
    05/03/2028
    HER-2 • PD-L1 • PIK3CA
    |
    PD-L1 expression • PIK3CA mutation
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Actemra IV (tocilizumab) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer (NCT05633979)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    02/09/2023
    Primary completion :
    12/31/2030
    Completion :
    12/31/2032
    HER-2 • UGT1A1
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Ezharmia (valemetostat)
    Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (NCT04379596)
    Phase 2
    AstraZeneca
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    06/03/2020
    Primary completion :
    07/30/2026
    Completion :
    07/30/2026
    HER-2
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (DESTINY-Breast11) (NCT05113251)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    10/25/2021
    Primary completion :
    03/12/2025
    Completion :
    04/30/2027
    HER-2
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • cyclophosphamide • Herzuma (trastuzumab-pkrb) • cyclophosphamide intravenous
    A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DESTINY-Breast08) (NCT04556773)
    Phase 1
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/05/2025
    Initiation :
    12/17/2020
    Primary completion :
    08/16/2023
    Completion :
    12/04/2025
    HER-2 • PGR
    |
    HER-2 expression • HER-2 underexpression • PGR positive
    |
    Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole
    Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer (NCT04294628)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/01/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    CD4
    |
    HER-2 positive • HER-2 amplification • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer (DS8201-A-U105) (NCT03523572)
    Phase 1
    Daiichi Sankyo
    Completed
    Last update posted :
    01/27/2025
    Initiation :
    08/02/2018
    Primary completion :
    07/22/2021
    Completion :
    09/12/2023
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer (ARTEMIDE-Gastric01) (NCT06764875)
    Phase 3
    AstraZeneca
    Not yet recruiting
    Last update posted :
    01/09/2025
    Initiation :
    03/28/2025
    Primary completion :
    04/27/2029
    Completion :
    12/09/2030
    PD-L1
    |
    Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936)
    A Multi-center Real-world Efficacy and Safety of Trastuzumab-deruxtecan in Advanced Gastric Cancer (NCT06767436)
    Phase N/A
    Yonsei University
    Recruiting
    Last update posted :
    01/09/2025
    Initiation :
    11/05/2024
    Primary completion :
    11/04/2025
    Completion :
    11/04/2025
    HER-2
    |
    HER-2 positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction (NCT05480384)
    Phase 2
    Brown University
    Recruiting
    Last update posted :
    11/25/2024
    Initiation :
    07/14/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2027
    HER-2
    |
    HER-2 overexpression • HER-2 amplification
    |
    Opdivo (nivolumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) (NCT05824975)
    Phase 1/2
    GI Innovation, Inc.
    Recruiting
    Last update posted :
    11/25/2024
    Initiation :
    05/30/2023
    Primary completion :
    11/12/2025
    Completion :
    04/24/2027
    CD8 • CD4
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • doxorubicin hydrochloride • Halaven (eribulin mesylate)
    Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer (DESTINY-CRC02) (NCT04744831)
    Phase 2
    Daiichi Sankyo
    Completed
    Last update posted :
    11/19/2024
    Initiation :
    03/05/2021
    Primary completion :
    11/01/2022
    Completion :
    10/08/2024
    EGFR • HER-2 • BRAF • TMB • MSI
    |
    MSI-H/dMMR • HER-2 overexpression • BRAF wild-type • RAS wild-type • HER-2 positive + RAS wild-type
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER) (NCT05965479)
    Phase 2
    University of Southampton
    Recruiting
    Last update posted :
    11/11/2024
    Initiation :
    04/10/2024
    Primary completion :
    03/31/2026
    Completion :
    04/30/2028
    HER-2
    |
    HER-2 overexpression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] (NCT03523585)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    11/05/2024
    Initiation :
    08/01/2018
    Primary completion :
    06/30/2022
    Completion :
    07/31/2025
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    lapatinib • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine
    Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02) (NCT04644237)
    Phase 2
    Daiichi Sankyo
    Completed
    Last update posted :
    10/24/2024
    Initiation :
    03/19/2021
    Primary completion :
    12/23/2022
    Completion :
    08/23/2024
    HER-2
    |
    HER-2 mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) (NCT04704934)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    10/24/2024
    Initiation :
    05/21/2021
    Primary completion :
    10/01/2025
    Completion :
    02/01/2026
    HER-2
    |
    HER-2 positive • HER-2 amplification
    |
    paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Cyramza (ramucirumab)
    A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) (NCT04622319)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    10/09/2024
    Initiation :
    12/04/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2030
    HER-2 • ER • PGR
    |
    HER-2 positive • HR positive • HER-2 expression • ER negative
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) ( DESTINY-Breast01) (NCT03248492)
    Phase 2
    Daiichi Sankyo
    Completed
    Last update posted :
    09/24/2024
    Initiation :
    08/25/2017
    Primary completion :
    03/21/2019
    Completion :
    05/06/2024
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Basket Study for Oligo-metastatic Breast Cancer (ANISE) (NCT05982678)
    Phase 2
    The Netherlands Cancer Institute
    Recruiting
    Last update posted :
    08/21/2024
    Initiation :
    05/02/2024
    Primary completion :
    10/01/2027
    Completion :
    10/01/2034
    HER-2 • ER
    |
    HER-2 positive • HER-2 amplification
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype (PONTIAC) (NCT06486883)
    Phase 2
    MedSIR
    Not yet recruiting
    Last update posted :
    07/04/2024
    Initiation :
    12/01/2024
    Primary completion :
    01/01/2027
    Completion :
    01/01/2028
    HER-2
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • fulvestrant
    A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations (DESTINY-Lung04) (NCT05048797)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    10/28/2021
    Primary completion :
    06/30/2025
    Completion :
    03/29/2027
    HER-2
    |
    HER-2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed
    DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] (NCT03529110)
    Phase 3
    Daiichi Sankyo
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    08/09/2018
    Primary completion :
    05/21/2021
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 positive • HER-2 expression
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03) (ACE-Breast-3) (NCT04829604)
    Phase 2
    Ambrx, Inc.
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    10/26/2021
    Primary completion :
    06/01/2025
    Completion :
    12/01/2026
    HER-2
    |
    HER-2 positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib) • anvatabart opadotin (JNJ-0683)
    ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer (NCT05650879)
    Phase 1
    Enliven Therapeutics
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    03/20/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2026
    BRAF • ALK • ROS1
    |
    HER-2 positive • BRAF V600E • HER-2 amplification • BRAF V600 • ALK mutation
    |
    Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • ELVN-002
    Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma (NCT04616560)
    Phase 2
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/06/2024
    Initiation :
    03/08/2021
    Primary completion :
    03/31/2025
    Completion :
    03/31/2025
    HER-2
    |
    HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene (NCI-2022-04099) (NCT05372614)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/05/2024
    Initiation :
    10/05/2022
    Primary completion :
    06/17/2024
    Completion :
    06/17/2024
    HER-2 • CD4 • CASP3
    |
    HER-2 positive • HER-2 overexpression • HER-2 amplification • HER-2 mutation • HER-2 L755S • HER-2 A775_G776insYVMA • HER-2 S310F • HER-2 V777L • HER-2 G778_P780dup • HER-2 D769Y • HER-2 L869R • HER-2 V842I • HER-2 H878Y • HER-2 L866M • HER-2 A775 • HER-2 G309A • HER-2 P780-Y781insGSP • HER-2 R678Q • HER-2 R896C • HER-2 T862A • HER-2 YVMA
    |
    Nerlynx (neratinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer (NCT04585958)
    Phase 1
    National Cancer Institute (NCI)
    Suspended
    Last update posted :
    06/05/2024
    Initiation :
    05/21/2021
    Primary completion :
    06/30/2024
    Completion :
    06/30/2024
    HER-2 • CD4
    |
    HER-2 positive • HER-2 negative • HER-2 expression
    |
    Lynparza (olaparib) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) (NCT06100874)
    Phase 2
    Adrienne G. Waks
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    11/20/2023
    Primary completion :
    11/30/2026
    Completion :
    11/30/2027
    HER-2
    |
    PGR expression
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA) (NCT03742102)
    Phase 1/2
    AstraZeneca
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    12/21/2018
    Primary completion :
    11/14/2024
    Completion :
    11/14/2024
    HER-2 • PD-L1
    |
    PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression
    |
    Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Truqap (capivasertib) • Datroway (datopotamab deruxtecan) • oleclumab (MEDI9447)
    T-DXd Therapy for HER2-low Breast Cancer Patients With Brain Metastases (TUXEDO-4) (NCT06048718)
    Phase 2
    MedSIR
    Not yet recruiting
    Last update posted :
    05/16/2024
    Initiation :
    05/31/2024
    Primary completion :
    09/01/2025
    Completion :
    07/01/2026
    HER-2
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer (NCT06085755)
    Phase 1/2
    Jeeyun Lee
    Not yet recruiting
    Last update posted :
    05/14/2024
    Initiation :
    06/01/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    HER-2
    |
    Gilotrif (afatinib) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer (NCT06058988)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    09/22/2023
    Primary completion :
    09/22/2027
    Completion :
    09/22/2027
    HER-2
    |
    HER-2 mutation • HER-2 expression
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)